Upstart Expansion bags a $55M launch round to join the hunt for RNA-targeting small molecules
Arrakis isn’t the only biotech startup looking to develop RNA-targeted small molecule drugs. Now they have a rival in Expansion Therapeutics, a San Diego-based biotech with R&D roots in the lab of Scripps’ Matthew Disney, who’s had a longtime interest exploring the field.
Expansion is having a coming out party this morning, celebrating a substantial $55.3 million launch round from some A-list investors: 5AM Ventures and Kleiner Perkins led the round, with help from Novartis Venture Fund, and Sanofi Ventures as well as participation from RA Capital Management and Alexandria Venture Investments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.